Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin

H. Hanenberg, C. Ding, K. Hashing, H. Konishi, K. Asada, I. Kalo, M. C. Dinauer, P. A. Williams

Research output: Contribution to journalArticle

Abstract

Efficient retroviral gene transfer (GT) into hematopoietic stem and progenitor cells can be achieved with retrovirus (RV) containing supernatant (SN) by colocalizing RV and target cells on specific adhesion domains of recombinant fibronectin fragments (FNF) (Hanenberg et al. Nat. Med. 2, 1996: 876). We further optimized this technology to target primary human clonogenic CD34+ cells obtained from bone marrow (BM) or from peripheral blood (PB) after mobilization with G-CSF. CD34+ BM ceils were prestimulated overnight with SCF and IL6. The next day, plates were coated with increasing concentrations (2, 8, 20, 50, 100 ug/cm2) of the FNF CH296 to which cells suspended in SN with an amphotropic NEO RV were added. GT efficiency assessed 12-16 days later as the number of G418' colonies did not increase with coating concentrations above 8 ug/cm2. Increasing the cell numbers from 500 to 625,000 per cm2 revealed that the GT efficiency was not influenced by the MOI over a range of 3 logs suggesting that the amount of RV particles present is not a limiting factor for transduction of CD34+ cells on CH-296. Next, CD34+ PB cells were prestimulated with various cytokine combinations for 1 or 2 days or directly put in the presence or absence of cytokines on CH-296 coated plates and then infected for two 4h transduction periods with NEO RV. The highest gene transfer efficiency occurred with a 40h prestimulation with SCF, G-CSF and MGDF (Artigen) achieving gene delivery of up to 69% of the clonogenic BM and PB CD34+ cells. Finally, we tested the following transduction protocols using SCF+IL6 or SCF+G-CSF+MGDF: A) no prestimulation, 40h RV+FN; B) 24h prestimulation, 24h RV+FN: C) 40h prestimulation, 8h RV+FN. Surprisingly, a prolonged incubation with RV+FN lowered the GT efficiency into clonogenic cells significantly (A vs. C). Preliminary data showed that a protocol using 40h prestimulation with 8h RV+FN can transduce NOD/SCID repopulating human PB CD34+ cells. These data demonstrate that FN-mediated genetic transduction of primary CD34+ cells may be well suited for genetic modifications of hematopoietic cells with retroviral vectors in clinically applicable protocols.

Original languageEnglish
Pages (from-to)880
Number of pages1
JournalExperimental Hematology
Volume25
Issue number8
StatePublished - 1997

Fingerprint

Retroviridae
Fibronectins
Infection
Genes
Granulocyte Colony-Stimulating Factor
Blood Cells
Hematopoietic Stem Cells
Genetic Transduction
Interleukin-6
Bone Marrow
Cytokines
Bone Marrow Cells
Cell Count
Technology

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Hanenberg, H., Ding, C., Hashing, K., Konishi, H., Asada, K., Kalo, I., ... Williams, P. A. (1997). Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin. Experimental Hematology, 25(8), 880.

Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin. / Hanenberg, H.; Ding, C.; Hashing, K.; Konishi, H.; Asada, K.; Kalo, I.; Dinauer, M. C.; Williams, P. A.

In: Experimental Hematology, Vol. 25, No. 8, 1997, p. 880.

Research output: Contribution to journalArticle

Hanenberg, H, Ding, C, Hashing, K, Konishi, H, Asada, K, Kalo, I, Dinauer, MC & Williams, PA 1997, 'Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin', Experimental Hematology, vol. 25, no. 8, pp. 880.
Hanenberg H, Ding C, Hashing K, Konishi H, Asada K, Kalo I et al. Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin. Experimental Hematology. 1997;25(8):880.
Hanenberg, H. ; Ding, C. ; Hashing, K. ; Konishi, H. ; Asada, K. ; Kalo, I. ; Dinauer, M. C. ; Williams, P. A. / Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin. In: Experimental Hematology. 1997 ; Vol. 25, No. 8. pp. 880.
@article{d6ed5cbe1b3b45328f3a3c0ffc687746,
title = "Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin",
abstract = "Efficient retroviral gene transfer (GT) into hematopoietic stem and progenitor cells can be achieved with retrovirus (RV) containing supernatant (SN) by colocalizing RV and target cells on specific adhesion domains of recombinant fibronectin fragments (FNF) (Hanenberg et al. Nat. Med. 2, 1996: 876). We further optimized this technology to target primary human clonogenic CD34+ cells obtained from bone marrow (BM) or from peripheral blood (PB) after mobilization with G-CSF. CD34+ BM ceils were prestimulated overnight with SCF and IL6. The next day, plates were coated with increasing concentrations (2, 8, 20, 50, 100 ug/cm2) of the FNF CH296 to which cells suspended in SN with an amphotropic NEO RV were added. GT efficiency assessed 12-16 days later as the number of G418' colonies did not increase with coating concentrations above 8 ug/cm2. Increasing the cell numbers from 500 to 625,000 per cm2 revealed that the GT efficiency was not influenced by the MOI over a range of 3 logs suggesting that the amount of RV particles present is not a limiting factor for transduction of CD34+ cells on CH-296. Next, CD34+ PB cells were prestimulated with various cytokine combinations for 1 or 2 days or directly put in the presence or absence of cytokines on CH-296 coated plates and then infected for two 4h transduction periods with NEO RV. The highest gene transfer efficiency occurred with a 40h prestimulation with SCF, G-CSF and MGDF (Artigen) achieving gene delivery of up to 69{\%} of the clonogenic BM and PB CD34+ cells. Finally, we tested the following transduction protocols using SCF+IL6 or SCF+G-CSF+MGDF: A) no prestimulation, 40h RV+FN; B) 24h prestimulation, 24h RV+FN: C) 40h prestimulation, 8h RV+FN. Surprisingly, a prolonged incubation with RV+FN lowered the GT efficiency into clonogenic cells significantly (A vs. C). Preliminary data showed that a protocol using 40h prestimulation with 8h RV+FN can transduce NOD/SCID repopulating human PB CD34+ cells. These data demonstrate that FN-mediated genetic transduction of primary CD34+ cells may be well suited for genetic modifications of hematopoietic cells with retroviral vectors in clinically applicable protocols.",
author = "H. Hanenberg and C. Ding and K. Hashing and H. Konishi and K. Asada and I. Kalo and Dinauer, {M. C.} and Williams, {P. A.}",
year = "1997",
language = "English",
volume = "25",
pages = "880",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Developing a clinically applicable protocol for gene transfer using retroviral infection on fibronectin

AU - Hanenberg, H.

AU - Ding, C.

AU - Hashing, K.

AU - Konishi, H.

AU - Asada, K.

AU - Kalo, I.

AU - Dinauer, M. C.

AU - Williams, P. A.

PY - 1997

Y1 - 1997

N2 - Efficient retroviral gene transfer (GT) into hematopoietic stem and progenitor cells can be achieved with retrovirus (RV) containing supernatant (SN) by colocalizing RV and target cells on specific adhesion domains of recombinant fibronectin fragments (FNF) (Hanenberg et al. Nat. Med. 2, 1996: 876). We further optimized this technology to target primary human clonogenic CD34+ cells obtained from bone marrow (BM) or from peripheral blood (PB) after mobilization with G-CSF. CD34+ BM ceils were prestimulated overnight with SCF and IL6. The next day, plates were coated with increasing concentrations (2, 8, 20, 50, 100 ug/cm2) of the FNF CH296 to which cells suspended in SN with an amphotropic NEO RV were added. GT efficiency assessed 12-16 days later as the number of G418' colonies did not increase with coating concentrations above 8 ug/cm2. Increasing the cell numbers from 500 to 625,000 per cm2 revealed that the GT efficiency was not influenced by the MOI over a range of 3 logs suggesting that the amount of RV particles present is not a limiting factor for transduction of CD34+ cells on CH-296. Next, CD34+ PB cells were prestimulated with various cytokine combinations for 1 or 2 days or directly put in the presence or absence of cytokines on CH-296 coated plates and then infected for two 4h transduction periods with NEO RV. The highest gene transfer efficiency occurred with a 40h prestimulation with SCF, G-CSF and MGDF (Artigen) achieving gene delivery of up to 69% of the clonogenic BM and PB CD34+ cells. Finally, we tested the following transduction protocols using SCF+IL6 or SCF+G-CSF+MGDF: A) no prestimulation, 40h RV+FN; B) 24h prestimulation, 24h RV+FN: C) 40h prestimulation, 8h RV+FN. Surprisingly, a prolonged incubation with RV+FN lowered the GT efficiency into clonogenic cells significantly (A vs. C). Preliminary data showed that a protocol using 40h prestimulation with 8h RV+FN can transduce NOD/SCID repopulating human PB CD34+ cells. These data demonstrate that FN-mediated genetic transduction of primary CD34+ cells may be well suited for genetic modifications of hematopoietic cells with retroviral vectors in clinically applicable protocols.

AB - Efficient retroviral gene transfer (GT) into hematopoietic stem and progenitor cells can be achieved with retrovirus (RV) containing supernatant (SN) by colocalizing RV and target cells on specific adhesion domains of recombinant fibronectin fragments (FNF) (Hanenberg et al. Nat. Med. 2, 1996: 876). We further optimized this technology to target primary human clonogenic CD34+ cells obtained from bone marrow (BM) or from peripheral blood (PB) after mobilization with G-CSF. CD34+ BM ceils were prestimulated overnight with SCF and IL6. The next day, plates were coated with increasing concentrations (2, 8, 20, 50, 100 ug/cm2) of the FNF CH296 to which cells suspended in SN with an amphotropic NEO RV were added. GT efficiency assessed 12-16 days later as the number of G418' colonies did not increase with coating concentrations above 8 ug/cm2. Increasing the cell numbers from 500 to 625,000 per cm2 revealed that the GT efficiency was not influenced by the MOI over a range of 3 logs suggesting that the amount of RV particles present is not a limiting factor for transduction of CD34+ cells on CH-296. Next, CD34+ PB cells were prestimulated with various cytokine combinations for 1 or 2 days or directly put in the presence or absence of cytokines on CH-296 coated plates and then infected for two 4h transduction periods with NEO RV. The highest gene transfer efficiency occurred with a 40h prestimulation with SCF, G-CSF and MGDF (Artigen) achieving gene delivery of up to 69% of the clonogenic BM and PB CD34+ cells. Finally, we tested the following transduction protocols using SCF+IL6 or SCF+G-CSF+MGDF: A) no prestimulation, 40h RV+FN; B) 24h prestimulation, 24h RV+FN: C) 40h prestimulation, 8h RV+FN. Surprisingly, a prolonged incubation with RV+FN lowered the GT efficiency into clonogenic cells significantly (A vs. C). Preliminary data showed that a protocol using 40h prestimulation with 8h RV+FN can transduce NOD/SCID repopulating human PB CD34+ cells. These data demonstrate that FN-mediated genetic transduction of primary CD34+ cells may be well suited for genetic modifications of hematopoietic cells with retroviral vectors in clinically applicable protocols.

UR - http://www.scopus.com/inward/record.url?scp=33748630525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748630525&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748630525

VL - 25

SP - 880

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 8

ER -